Dova Pharmaceuticals CEO Alex Sapir removed, David Zaccardelli to succeed

Dova Pharmaceuticals (DOVA) announced that David Zaccardelli has been appointed president and CEO. Zaccardelli brings specialty pharmaceutical executive leadership and operational expertise, including most notably, serving in several senior management roles at United Therapeutics (UTHR). In addition, Jason Hoitt, a seasoned pharmaceutical sales and marketing executive, joins Dova as CCO. Alex Sapir, the company’s prior president and CEO, is no longer president and CEO, effective as of December 16.
https://thefly.com/landingPageNews.php?id=2837793